Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Beyond Air Inc (Beyond Air) is a clinical-stage biopharmaceutical company focused on utilizing nitric oxide (NO) to improve patient outcomes in respiratory illnesses, neurological disorders, and solid tumors. the company is in the development and provision of products and services related to nitric oxide therapies. Its products include the nitric oxide (no2) filter for pulmonary hypertension of the newborn and cardiac surgery, lungfitph for viral community-acquired pneumonia and cardiac surgery, lungfitpro for viral community-acquired pneumonia and bronchiolitis, and lungfitgo for nontuberculous mycobacteria (ntm) lung infection. The company’s service offerings include clinical support services, lungfit ph system and services, comprehensive live on-demand training services. Beyond Air is headquartered in Garden City, New York, the US.
Headquarters
United States of America
Address
Suite 301, 900 Stewart Avenue, Garden City, New York, 11530
Website
www.beyondair.net
Telephone
1 516 6658200
No of Employees
54
Industry
Medical Equipment
Ticker Symbol & Exchange
XAIR (NASD)
Revenue (2025)
$7.7M
107.3%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
28.7%
(2025 vs 2024)
Market Cap*
$4.0M
Net Profit Margin (2025)
XYZ
65.6%
(2025 vs 2024)
* As of and is in US$
Products and Services
| Products | Services | Brands |
|---|---|---|
| Product: | Clinical Support Services | Air |
| Nitric Oxide (NO2) Filter: | Comprehensive Live On-Demand Training Services | |
| LungFitPH | LungFit PH System and Services | |
| XYZ | ||
| XYZ | ||
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In October, the company entered into an agreement with Vizient, Inc to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors. |
| 2026 | Others | In March, the company cancelled to sell 85% stake in NeuroNos Limited to XTL Biopharmaceuticals Ltd. |
Competitor Comparison
| Key Parameters | Beyond Air Inc | Boehringer Ingelheim Pharmaceuticals Inc | GlaxoSmithKline LLC | AstraZeneca Pharmaceuticals LP |
|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America |
| City | Garden City | Ridgefield | Philadelphia | Wilmington |
| State/Province | New York | Connecticut | Pennsylvania | Delaware |
| No. of Employees | 54 | - | 15,000 | 18,000 |
| Entity Type | Public | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Steve Lisi | Chairman; Chief Executive Officer | Executive Board | 2017 | - |
| Dan Moorhead | Chief Financial Officer | Senior Management | 2026 | - |
| Michael Gaul | Chief Operating Officer | Senior Management | 2023 | - |
| John Jett,Ph.D. | Head - Research and Clinical Development | Senior Management | - | - |
| Duke Drewell | Controller | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer